Radiopharm Theranostics Ltd Depositary Receipt (RADX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Brokerages
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy
Radiopharm Theranostics Ltd Depositary Receipt Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RB Robert Burns HC Wainwright & Co. | 1,127.8 | $5,221.73 | $4,815.72 | -$406.01 | -7.78% |
Radiopharm Theranostics Ltd Depositary Receipt (RADX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Radiopharm Theranostics Ltd Depositary Receipt ever had a stock split?
Radiopharm Theranostics Ltd Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Riccardo Canevari CEO | NASDAQ (CM) Exchange | 75041J101 CUSIP |
| AU Country | 14 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Radiopharm Theranostics Limited is an innovative company focused on the development of novel radiopharmaceuticals for both diagnostic and therapeutic applications, targeting diseases with high medical needs. Since its inception in 2021, the company has been dedicated to advancing its pipeline of proprietary radiopharmaceutical candidates to address various types of cancers. With its headquarters located in Carlton, Australia, Radiopharm Theranostics is forging paths in the medical field through its strategic collaborations, notably with Lantheus Holdings, Inc., which aims to expedite the clinical development of its groundbreaking radiopharmaceuticals.
Products and Services
- RAD 204
A cutting-edge therapeutic agent targeting programmed death-ligand 1 (PD-L1), RAD 204 is designed for the treatment of non-small cell lung cancer (NSCLC), offering a potential new avenue for addressing this prevalent type of lung cancer.
- RAD 202
This candidate focuses on targeting human epidermal growth factor receptor 2 (HER2), aimed at treating breast cancer and a variety of other solid tumors. RAD 202 represents a promising approach in the fight against these challenging conditions.
- RAD 301
As a diagnostic tool, RAD 301 targets avß6 integrin, primarily in patients with pancreatic ductal adenocarcinoma. This radiopharmaceutical aims to enhance the accuracy of diagnosing this aggressive type of pancreatic cancer.
- RAD 302
Also targeting avß6-integrin, RAD 302 is under development for the treatment of multiple cancer types, highlighting the versatility and broad applicability of Radiopharm Theranostics' targeting strategies.
- RAD 101 and RAD 102
These agents are aimed at addressing brain metastases, providing hope for patients with cancers that have spread to the brain. They represent the company’s commitment to tackling some of the most difficult-to-treat aspects of cancer.
- RAD 402
Targeting advanced prostate cancer, RAD 402 is in development to offer a new therapeutic option for patients battling this common yet challenging condition.
- RV01
Designed for the treatment of multiple solid tumors, RV01 embodies the company’s broad approach to cancer therapeutics, potentially benefiting a wide range of patients with different types of solid tumors.
